Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
Authors:
- 20 December 2001
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 115 (3) , 605-608
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Thalidomide — A Revival StoryNew England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin’s LymphomaBlood, 1999
- Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple MyelomaBlood, 1999
- Syndecan-1 (CD 138) in Myeloma and Lymphoid Malignancies: A Multifunctional Regulator of Cell Behavior Within the Tumor MicroenvironmentLeukemia & Lymphoma, 1999
- Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple MyelomaBlood, 1998
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.Journal of Cell Biology, 1992
- Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.Proceedings of the National Academy of Sciences, 1987